Treatment for Menstrual Irregularities Without a Clear Cause
For menstrual irregularities without an identified cause, tranexamic acid (TXA) is the first-line treatment, followed by desmopressin (DDAVP) or combined oral contraceptive pills (COCPs) as second-line options. 1
First-Line Treatment Options
Tranexamic Acid (TXA)
- Works by inhibiting fibrinolysis, thereby reducing menstrual blood loss
- Recommended as the primary intervention for heavy menstrual bleeding in women with bleeding disorders of unknown cause (BDUC)
- Can be used during days of bleeding (typically 5-7 days)
- Does not affect future fertility
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Recommended for short-term treatment (5-7 days) during days of bleeding 2
- Acts by inhibiting prostaglandin synthesis
- Options include:
- Ibuprofen
- Mefenamic acid (an effective alternative for reducing bleeding)
Second-Line Treatment Options
Desmopressin (DDAVP)
- Increases von Willebrand factor and factor VIII levels
- Particularly useful when bleeding persists despite first-line therapy
- Can be used in combination with TXA for more severe cases
Hormonal Contraceptives
- Combined oral contraceptive pills (COCPs) are effective for regulating menstrual cycles 3
- Particularly beneficial for women with anovulation or oligoovulation
- Provides the added benefit of reducing risks of endometrial hyperplasia and cancer
- Monitor for potential side effects:
- Breakthrough bleeding and spotting (especially during first three months) 4
- Headaches
- Changes in blood pressure
Levonorgestrel-Releasing Intrauterine Device (LNG-IUD)
- Effectively reduces menstrual bleeding 2
- No increased risk of thrombosis
- Long-acting option (effective for 3-7 years depending on the type)
- May be particularly beneficial for women with heavy menstrual bleeding
Third-Line Treatment Options
Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists
- Can significantly reduce bleeding symptoms 2
- May have hypoestrogenic side effects such as hot flashes and loss of bone mineral density
- GnRH antagonists (elagolix, linzagolix, relugolix) can be combined with low-dose estrogen and progestin to mitigate side effects
Treatment Algorithm Based on Severity and Response
For mild to moderate menstrual irregularities:
- Start with TXA during days of bleeding
- Add NSAIDs if cramping is also present
If inadequate response to first-line therapy:
- Add DDAVP or switch to hormonal contraception (COCP)
- Consider LNG-IUD for long-term management
For persistent heavy bleeding despite second-line therapy:
- Consider combination therapy (TXA + DDAVP)
- Evaluate for underlying conditions that may have been missed
Important Considerations
- Rule out pregnancy before initiating hormonal treatments 4
- Non-hormonal causes should be considered for breakthrough bleeding
- For women with amenorrhea, pregnancy should be ruled out before continuing treatment
- Monitor women with a history of depression when using hormonal contraceptives
- Changing to an oral contraceptive with higher estrogen content may help with menstrual irregularity but increases the risk of thromboembolic disease 4
Lifestyle Modifications
- For overweight or obese women, dietary and lifestyle modifications should be implemented alongside medical treatment 3
- Managing life stresses can help alleviate symptoms 5
- Regular physical activity (without excessive exercise that could cause exercise-related menstrual abnormalities) 6
Monitoring and Follow-up
- Regular follow-up is essential to assess treatment response
- If two consecutive periods are missed while on treatment, pregnancy should be ruled out 4
- Evaluate for persistent adverse effects or adherence issues
- Consider changing treatment approach if inadequate response after 3 months
Menstrual irregularities can significantly impact quality of life and may be associated with various health conditions including metabolic syndrome, coronary heart disease, and type 2 diabetes mellitus 7. Therefore, proper treatment is essential not only for symptom management but also for long-term health outcomes.